seed
Stage
3
Investors
About
Alveogene is developing inhaled gene therapies for rare respiratory diseases using a proprietary lentiviral delivery platform called InGenuiTy™, allowing efficient transduction of lung epithelial cells with long duration of action.
Explore Alveogene's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.